Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Amneal Pharmaceuticals received FDA approval for additional strengths and vial presentations of iohexol injection (350 mg iodine/mL and 300 mg iodine/mL), with planned Q3 2026 launch. The expanded portfolio is expected to address the majority of U.S. iohexol injection market demand, which generated approximately $706 million in annual sales as of May 2026.